Clinical trial NCT03730948: DC Vaccine in Colorectal Cancer
Official title: Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Colorectal Cancer
Keywords: colorectal cancer
cancer vaccine
dendritic cell vaccine
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Parker Institute for Cancer Immunotherapy
name: National Cancer Institute (NCI)
First posted: 2018-11-05
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.

Detailed description: This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.

Eligible patients that provide written informed consent will undergo apheresis to collect blood mononuclear cells for vaccine production approximately 1 week prior to vaccine infusion. Each study subject will receive cyclophosphamide 300mg/m\^2 intravenously 3 to 4 days prior to the vaccine dose to deplete regulatory T cells. For each vaccine dose, all subjects will receive autologous dendritic cells pulsed with mutated peptides. On Day 1, the subject will receive the primer vaccine dose; this will be followed by one booster vaccine dose approximately 8 weeks later. Peripheral blood will be taken weekly, and a second apheresis procedure will be performed at the end of study to monitor the immune response to the vaccine. Information will be gathered from usual clinic visits for approximately 1 year following the End of Treatment Study Visit to evaluate for disease progression.

Eligibility criteria: Inclusion Criteria:

* Pathologically-confirmed stage I and II hypermutated colorectal cancer (CRC)
* Surgically resected disease
* Male or female patients 18+ years of age
* ECOG performance status 0-1
* Certain laboratory values, performed within 14 days prior to consent
* Subjects of reproductive potential must agree to use a medically accepted birth control method during the trial and for at least two months following the trial.
* Provide written informed consent

Exclusion Criteria:

* Prior malignancy within 3 years that may put subject at risk
* Pregnant or nursing women
* Concurrent treatment with systemic immunosuppressants including corticosteroids, calcineurin inhibitors, antiproliferative agents within 2 weeks of consent. Local (inhaled or topical) steroids or replacement dose prednisone are permitted.
* Known allergy to eggs
* Any uncontrolled intercurrent illness or active ongoing infection thta may put subject at additional risk

Primary outcomes:
measure: Changes in Numbers of Peptide-specific CD8+ T Cells (Post-vaccine Immune Response)
timeFrame: Screening, Day 1, Day 43, Day 85. Also at following timepoints, which will vary by subject: 7-14 days after last vaccine; 30 days after last vaccine; every 3 months beginning 6 months since first vaccine until month 12.
measure: Adverse Events Experienced by Subjects (i.e. Safety of DC Vaccine in Subjects With Surgically Resected Hypermutated CRC)
timeFrame: Through study completion (at 12 months)
Secondary outcomes:
measure: Percentage of CD8+ Cells in Primary Tumor Tissue
timeFrame: Screening, Day 1, Day 43, Day 85. Also at following timepoints, which will vary by subject: 7-14 days after last vaccine; 30 days after last vaccine; every 3 months beginning 6 months since first vaccine until month 12.
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Kim Reiss-Binder, MD
role: PRINCIPAL_INVESTIGATOR
References: